Prothya Biosolutions

Prothya Biosolutions is a global provider of plasma-derived medicinal products and services, formed in 2021 through the integration of Plasma Industries Belgium and Sanquin Plasma Products. The company combines over 60 years of legacy expertise in plasma fractionation with a mission to deliver life-saving therapies for patients with immunological and critical care needs. It operates a dual business model, commercializing its own branded products while offering CDMO services to other healthcare organizations. Prothya is positioned as a specialized player in the stable and growing plasma therapeutics market.

Industrial-scale plasma fractionation and purification platform for isolating therapeutic proteins (immunoglobulins, albumin, clotting factors) from human plasma.

Prothya competes in a market dominated by a handful of large, vertically integrated global players like Takeda, CSL Behring, Grifols, and Octapharma. Its differentiation lies in its specialized European focus, dual product/CDMO model, and legacy expertise from blood service organizations, positioning it as a niche, high-quality alternative.